Do analysts rate PBYI or EDSA?

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 27.11%. Given Edesa Biotech's higher probable upside, analysts clearly believe Edesa Biotech is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, LRMR or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is LRMR or EDSA more profitable?

Larimar Therapeutics' return on equity of -134.14% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Edesa Biotech N/A -286.52% -75.36%

Do analysts recommend EDSA or AVIR?

Edesa Biotech presently has a consensus target price of $5.00, suggesting a potential downside of 27.11%. Given Edesa Biotech's higher probable upside, equities analysts plainly believe Edesa Biotech is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation & earnings, EDSA or AVIR?

Edesa Biotech is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.34 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is EDSA or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% Atea Pharmaceuticals N/A -57.01% -51.49%

Is EDSA or CLLS more profitable?

Edesa Biotech has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% Cellectis -89.51% -80.66% -20.51%

Which has stronger valuation & earnings, IMRX or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is IMRX or EDSA more profitable?

Immuneering's return on equity of -31.93% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Edesa Biotech N/A -286.52% -75.36%

Edesa Biotech (EDSA) Competitors

$6.86 +0.03 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$6.95 +0.09 (+1.31%)

As of 06:04 PM Eastern

Compare

EDSA vs. PBYI, LRMR, AVIR, CLLS, and IMRX

Should you buy Edesa Biotech stock or one of its competitors? MarketBeat compares Edesa Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edesa Biotech include Puma Biotechnology (PBYI), Larimar Therapeutics (LRMR), Atea Pharmaceuticals (AVIR), Cellectis (CLLS), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.

How does Edesa Biotech compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

In the previous week, Edesa Biotech had 5 more articles in the media than Puma Biotechnology. MarketBeat recorded 6 mentions for Edesa Biotech and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.94 beat Edesa Biotech's score of -0.30 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Positive
Edesa Biotech	Neutral

Puma Biotechnology has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.52	$31.11M	$0.48	14.19
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Puma Biotechnology has a net margin of 10.69% compared to Edesa Biotech's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Edesa Biotech	N/A	-286.52%	-75.36%

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Puma Biotechnology has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 27.11%. Given Edesa Biotech's higher probable upside, analysts clearly believe Edesa Biotech is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Puma Biotechnology beats Edesa Biotech on 10 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Larimar Therapeutics presently has a consensus price target of $15.29, indicating a potential upside of 377.68%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 27.11%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edesa Biotech is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

In the previous week, Edesa Biotech had 3 more articles in the media than Larimar Therapeutics. MarketBeat recorded 6 mentions for Edesa Biotech and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.54 beat Edesa Biotech's score of -0.30 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Larimar Therapeutics	Positive
Edesa Biotech	Neutral

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Larimar Therapeutics' return on equity of -134.14% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Edesa Biotech	N/A	-286.52%	-75.36%

Larimar Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Summary

Larimar Therapeutics beats Edesa Biotech on 8 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to Atea Pharmaceuticals?

Edesa Biotech (NASDAQ:EDSA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Edesa Biotech had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for Edesa Biotech and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.04 beat Edesa Biotech's score of -0.30 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Neutral
Atea Pharmaceuticals	Positive

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Atea Pharmaceuticals' return on equity of -57.01% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Edesa Biotech presently has a consensus target price of $5.00, suggesting a potential downside of 27.11%. Given Edesa Biotech's higher probable upside, equities analysts plainly believe Edesa Biotech is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Edesa Biotech has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Edesa Biotech is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Summary

Edesa Biotech and Atea Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to Cellectis?

Edesa Biotech (NASDAQ:EDSA) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market.

Edesa Biotech has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Cellectis	-89.51%	-80.66%	-20.51%

Edesa Biotech has higher earnings, but lower revenue than Cellectis. Edesa Biotech is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Cellectis	$79.59M	3.90	-$67.59M	-$0.67	N/A

Edesa Biotech currently has a consensus price target of $5.00, suggesting a potential downside of 27.11%. Cellectis has a consensus price target of $7.00, suggesting a potential upside of 126.54%. Given Cellectis' stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Edesa Biotech had 3 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Edesa Biotech and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.44 beat Edesa Biotech's score of -0.30 indicating that Cellectis is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Neutral
Cellectis	Positive

Summary

Cellectis beats Edesa Biotech on 12 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Edesa Biotech is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Immuneering currently has a consensus target price of $16.50, suggesting a potential upside of 262.64%. Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 27.11%. Given Immuneering's stronger consensus rating and higher probable upside, equities research analysts plainly believe Immuneering is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Edesa Biotech had 1 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Edesa Biotech and 5 mentions for Immuneering. Immuneering's average media sentiment score of 0.07 beat Edesa Biotech's score of -0.30 indicating that Immuneering is being referred to more favorably in the media.

Company	Overall Sentiment
Immuneering	Neutral
Edesa Biotech	Neutral

67.7% of Immuneering shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Immuneering's return on equity of -31.93% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Edesa Biotech	N/A	-286.52%	-75.36%

Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Summary

Immuneering beats Edesa Biotech on 10 of the 14 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$60.99M	$3.28B	$6.25B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-5.12	17.93	22.29	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	15.24	6.63	9.84	6.72
Net Income	-$7.19M	$24.20M	$3.57B	$337.19M
7 Day Performance	-13.93%	-3.24%	-1.17%	0.48%
1 Month Performance	-61.00%	0.53%	3.84%	5.06%
1 Year Performance	244.72%	47.24%	27.39%	34.27%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	1.966 of 5 stars	$6.86 +0.4%	$5.00 -27.1%	+243.2%	$60.99M	N/A	N/A	20	Short Interest Decrease
PBYI Puma Biotechnology	1.2395 of 5 stars	$7.27 +2.7%	N/A	+112.2%	$360.37M	$228.40M	15.15	200	Positive News
LRMR Larimar Therapeutics	2.4475 of 5 stars	$3.47 +0.6%	$16.33 +370.7%	+50.0%	$358.40M	N/A	N/A	30
AVIR Atea Pharmaceuticals	1.0072 of 5 stars	$4.53 +2.5%	N/A	+37.7%	$353.72M	N/A	N/A	70
CLLS Cellectis	3.0855 of 5 stars	$3.67 +4.9%	$6.75 +83.9%	+126.8%	$351.19M	$68.07M	N/A	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. PBYI, LRMR, AVIR, CLLS, and IMRX

How does Edesa Biotech compare to Puma Biotechnology?

Summary

How does Edesa Biotech compare to Larimar Therapeutics?

Summary

How does Edesa Biotech compare to Atea Pharmaceuticals?

Summary

How does Edesa Biotech compare to Cellectis?

Summary

How does Edesa Biotech compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. PBYI, LRMR, AVIR, CLLS, and IMRX

How does Edesa Biotech compare to Puma Biotechnology?

Does the media prefer PBYI or EDSA?

Which has higher earnings and valuation, PBYI or EDSA?

Is PBYI or EDSA more profitable?

Do institutionals & insiders hold more shares of PBYI or EDSA?

Which has more risk and volatility, PBYI or EDSA?

Do analysts rate PBYI or EDSA?

Summary

How does Edesa Biotech compare to Larimar Therapeutics?

Do analysts recommend LRMR or EDSA?

Which has better valuation & earnings, LRMR or EDSA?

Does the media prefer LRMR or EDSA?

Do insiders and institutionals believe in LRMR or EDSA?

Is LRMR or EDSA more profitable?

Which has more volatility & risk, LRMR or EDSA?

Summary

How does Edesa Biotech compare to Atea Pharmaceuticals?

Does the media refer more to EDSA or AVIR?

Do insiders & institutionals hold more shares of EDSA or AVIR?

Is EDSA or AVIR more profitable?

Do analysts recommend EDSA or AVIR?

Which has more risk and volatility, EDSA or AVIR?

Which has better valuation & earnings, EDSA or AVIR?

Summary

How does Edesa Biotech compare to Cellectis?

Do institutionals & insiders hold more shares of EDSA or CLLS?

Which has more volatility and risk, EDSA or CLLS?

Is EDSA or CLLS more profitable?

Which has higher valuation & earnings, EDSA or CLLS?

Do analysts rate EDSA or CLLS?

Does the media favor EDSA or CLLS?

Summary

How does Edesa Biotech compare to Immuneering?

Which has stronger valuation & earnings, IMRX or EDSA?

Do analysts prefer IMRX or EDSA?

Does the media prefer IMRX or EDSA?

Do institutionals & insiders believe in IMRX or EDSA?

Is IMRX or EDSA more profitable?

Which has more risk & volatility, IMRX or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools